Adar1 Capital Management, Llc Buys 6,009 Shares of Rallybio (NASDAQ:RLYB) Stock

Posted by Stanley Muller on May 20th, 2026

Rallybio Corporation (NASDAQ:RLYB – Get Free Report) major shareholder Adar1 Capital Management, Llc bought 6,009 shares of the stock in a transaction that occurred on Monday, May 18th. The stock was bought at an average cost of $13.98 per share, for a total transaction of $84,005.82. Following the completion of the purchase, the insider directly owned 916,152 shares of the company’s stock, valued at $12,807,804.96. This represents a 0.66% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

On Tuesday, May 19th, Adar1 Capital Management, Llc bought 10,200 shares of Rallybio stock. The stock was bought at an average cost of $13.98 per share, for a total transaction of $142,596.00.
On Friday, May 15th, Adar1 Capital Management, Llc bought 300 shares of Rallybio stock. The stock was bought at an average cost of $13.90 per share, for a total transaction of $4,170.00.
On Wednesday, May 13th, Adar1 Capital Management, Llc bought 79,259 shares of Rallybio stock. The stock was bought at an average cost of $13.99 per share, for a total transaction of $1,108,833.41.
On Tuesday, May 12th, Adar1 Capital Management, Llc bought 800 shares of Rallybio stock. The stock was bought at an average cost of $13.83 per share, for a total transaction of $11,064.00.
On Monday, May 11th, Adar1 Capital Management, Llc bought 50,000 shares of Rallybio stock. The stock was bought at an average cost of $14.00 per share, for a total transaction of $700,000.00.
On Tuesday, May 5th, Adar1 Capital Management, Llc bought 35,101 shares of Rallybio stock. The stock was bought at an average cost of $14.00 per share, for a total transaction of $491,414.00.
On Monday, May 4th, Adar1 Capital Management, Llc bought 120,804 shares of Rallybio stock. The stock was bought at an average cost of $13.97 per share, for a total transaction of $1,687,631.88.

Rallybio Stock Performance

RLYB traded up $0.39 on Wednesday, reaching $14.58. The company had a trading volume of 43,720 shares, compared to its average volume of 642,666. The business has a 50 day simple moving average of $10.05 and a 200 day simple moving average of $7.25. The company has a market cap of $77.27 million, a price-to-earnings ratio of -3.20 and a beta of -1.10. Rallybio Corporation has a 52-week low of $2.16 and a 52-week high of $15.31.

Rallybio (NASDAQ:RLYB – Get Free Report) last announced its earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.26). Rallybio had a negative net margin of 911.07% and a negative return on equity of 55.79%. The company had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.21 million.

Hedge Funds Weigh In On Rallybio

Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC boosted its holdings in Rallybio by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after acquiring an additional 2,996 shares during the period. XTX Topco Ltd boosted its holdings in Rallybio by 64.6% during the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after acquiring an additional 38,205 shares during the period. Susquehanna International Group LLP boosted its holdings in Rallybio by 485.9% during the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after acquiring an additional 113,031 shares during the period. Renaissance Technologies LLC boosted its holdings in Rallybio by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after acquiring an additional 120,892 shares during the period. Finally, Citadel Advisors LLC boosted its holdings in Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after acquiring an additional 373,821 shares during the period. Institutional investors and hedge funds own 90.34% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on RLYB. Wall Street Zen upgraded Rallybio to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rallybio in a research report on Friday, May 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

View Our Latest Report on RLYB

About Rallybio

(Get Free Report)

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.